Diagnosis

People with a history of breast cancer may want to consider COVID and flu vaccinations, according to the researchers.

Risks were higher for a new cancer in the opposite breast, as well as ovarian, pancreatic, and prostate cancers.

Does being diagnosed with breast cancer after giving birth affect survival?

How do obesity and metabolic syndrome affect breast cancer outcomes?

Higher numbers of certain white blood cells in a tumor may mean triple-negative breast cancer is less likely to come back.

Being older when having your first child and breastfeeding seem to offer some protection against triple-negative breast cancer.

If DCIS is found before regular mammograms start or in between regular screening, it more than quadruples the risk of invasive breast cancer.

Breast cancer death rates in the United States dropped by nearly 60% between 1975 and 2019.

Cancer cases are increasing in people younger than 50, especially in younger women.

Pausing radiation therapy for triple-negative breast cancer for even just two days is linked to worse survival.

Considering information on stage and receptor status can help doctors personalize breast cancer follow-up care.

Tukysa plus the standard of care improved survival in people diagnosed with metastatic, HER2-positive breast cancer that had spread to the brain.

For women ages 65 and older diagnosed with small, early-stage, hormone receptor-positive breast cancer, radiation after lumpectomy didn’t improve overall survival, but it did dramatically reduce the risk of recurrence.

Trodelvy is now approved to treat metastatic, hormone receptor-positive breast cancer, rather than only triple-negative disease.

Mutations in four genes linked to breast cancer greatly increase cancer risk in the opposite breast.

The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation.

Four more years of follow-up continue to show that women with an Oncotype DX Breast Recurrence Score of 11-25 can safely skip chemotherapy; their risk or recurrence wasn’t higher than women who received chemotherapy.

Pre-menopausal women diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer got more benefits from Kisqali and hormonal therapy than chemotherapy as a first treatment.

The benefits of Verzenio after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence were confirmed with longer follow-up.

Updated results from the DESTINY-Breast02 and DESTINY-Breast03 studies confirmed the benefits of Enhertu for previously treated metastatic, HER2-positive breast cancer, and results from the TALENT trial suggest that the medicine may offer benefits for early-stage hormone receptor-positive, HER2-low breast cancer when given before surgery.

Women diagnosed with early-stage breast cancer receiving anthracycline chemotherapy who completed a 12-month exercise program had a lower risk of functional problems and better cardiovascular health.

Treating early-stage breast cancer with radiation along with chemotherapy and hormonal therapy after lumpectomy lowers recurrence risk in the same breast, but doesn’t improve overall survival.

Post-menopausal women with a history of early-stage disease who did even moderate exercise, such as fast walking or easy cycling, reduced their risk of dying from breast cancer.

Switching from an aromatase inhibitor and Ibrance to Faslodex and Ibrance as the first treatment for advanced-stage, estrogen receptor-positive breast cancer seemed to overcome treatment resistance caused by ESR1 mutations.